Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BGB-A445 |
Trade Name | |
Synonyms | BGB A445|BGBA445 |
Drug Descriptions |
BGB-A445 is an activating anti-TNFRSF4 (OX40) antibody that does not block binding to its ligand, OX40L, potentially resulting in increased immune response and anti-tumor activity (Journal for ImmunoTherapy of Cancer 2020;8:699). |
DrugClasses | OX40 Antibody 14 |
CAS Registry Number | NA |
NCIT ID | C175453 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BGB-A445 | BGB-A445 | 0 | 1 |
BGB-A445 + Carboplatin + Tislelizumab | BGB-A445 Carboplatin Tislelizumab | 0 | 0 |
BGB-A445 + Cisplatin + Tislelizumab | BGB-A445 Cisplatin Tislelizumab | 0 | 0 |
BGB-A445 + Nab-paclitaxel + Tislelizumab | BGB-A445 Nab-paclitaxel Tislelizumab | 0 | 0 |
BGB-A445 + Paclitaxel + Tislelizumab | BGB-A445 Paclitaxel Tislelizumab | 0 | 0 |
BGB-A445 + Pemetrexed Disodium + Tislelizumab | BGB-A445 Pemetrexed Disodium Tislelizumab | 0 | 0 |
BGB-A445 + Tislelizumab | BGB-A445 Tislelizumab | 0 | 2 |